###### Key questions

What is already known?
======================

-   The number of people receiving renal replacement therapy (mainly dialysis) for end-stage kidney disease (ESKD) is already over 2.5 million and is expected to exceed 5 million within a decade.

-   Yet, no systematic global description of the participation of treatment centres in large, multicentre, randomised clinical trials has ever been undertaken.

What are the new findings?
==========================

-   Enormous disparities in randomised research participation around the globe exist, with relative site representation being as low as 5% what would be expected from the number of dialysis recipients alone.

-   Moreover, global regions with growing dialysis populations, especially in Asia and Africa, remain markedly under-represented.

What do the new findings imply?
===============================

-   Clinicians, guideline writers and policymakers in under-represented regions should be alert to the potential challenges of generalising the results of key randomised trials to their local populations.

-   The nephrology community should strive to build research networks to foster relevant clinical research, including clinicians and participants from regions facing a growing burden of ESKD.

Introduction {#s1}
============

By 2030, over 5 million people around the world are expected to be receiving kidney replacement therapy (KRT) for end-stage kidney disease (ESKD), with much of the growth to come from regions outside of Europe and North America.[@R1] The majority of these individuals will receive dialysis (whether haemo- or peritoneal), resulting in a growing diversity of dialysis populations defined by differing patient characteristics, health system practices and resource availability. These differences ought to be reflected in the available clinical evidence as therapies proven to work in one context may be unavailable, or less effective, in another. Moreover, while many aspects of dialysis therapy and evidence are universally relevant, many clinical questions differ in importance to patients, clinicians and healthcare providers, depending on their location, available resources and context.[@R2]

Randomised controlled trials (RCTs) play an essential role in advancing clinical knowledge and improving patient care, yet for their results to be applied, they must have a reasonable degree of external validity (or generalisability).[@R3] Generalisable trials tend to enrol a larger number of participants from multiple sites to ensure that the intervention can be seen to work in a range of patients and settings. Such trials are, therefore, critically important to clinicians, healthcare providers and health economists when making patient treatment and resource-allocation decisions. Unfortunately, despite rapid growth in the burden of non-communicable diseases, the output of RCTs from low-income and middle-income countries is believed to be meagre.[@R2] There has, however, been little formal study of this issue in nephrology. In this context, we hypothesised that, despite the global growth in dialysis recipients, low-middle-income countries would be poorly represented in recruitment to large, potentially generalisable dialysis trials. To test this hypothesis, we systematically reviewed large dialysis RCTs and compared trial participant recruitment to a number of dialysis patients in each of the 10 International Society of Nephrology (ISN) global regions.

Methods {#s2}
=======

A systematic search of MEDLINE, PubMed and the Cochrane Central Register of Controlled Trials was conducted for RCTs that had enrolled at least 100 participants from at least two sites, with participants who were on maintenance dialysis for ESKD at the time of randomisation. Studies published between 01 January 2007 and 31 December 2016 were included. Studies were excluded if they enrolled participants aged \<18 years, with acute kidney injury, or with or about to receive a kidney transplant. No language restrictions were applied. No definition of 'site' was made *a priori*, and the number of sites was determined according to each study author's description.

After removal of duplicates, titles and abstracts were screened independently by two of the three lead researchers (BS, AH and KT) for inclusion and exclusion criteria. Discrepancies between the two primary researchers were adjudicated by the third. Where multiple publications relating to the same trial cohort were identified, the earliest published manuscript was selected to be the primary source of information, such that no trial cohort could be counted more than once.

Data from each included study were then independently extracted by two researchers using a purpose-built online case report form. Material from supplementary online appendices, secondary publications and online trial registration information was also accessed, if necessary, to ascertain the required information. Discrepancies in extracted data were resolved by discussion among the researchers.

Extracted data items included the number of randomised participants, number of sites (centres could be counted more than once if they happened to participate in more than one study) and their country of location. Study characteristics, such as sponsor type, blinding, type of randomisation and intervention, and baseline participant characteristics, were also extracted as part of an associated project to compare the characteristics of enrolled study participants versus the dialysis registry population. The results of this project are presented elsewhere[@R4] and the study protocol is registered online (PROSPERO ID: CRD42018090862).

The primary outcome of this study was a novel measure of the representation of each global region in RCTs, developed specifically for the present analysis and hereafter referred to as the 'representation index' (RI). This unit-less ratio is defined by the proportion of trial sites identified in each global region (number of trial sites in a global region divided by the total number of trial sites identified worldwide) divided by the proportion of dialysis patients in that region (number of dialysis patients in that region divided by total number of patients receiving dialysis worldwide). The number of dialysis patients worldwide and in each ISN region was derived from the estimates published by Liyanage *et al*.[@R1] The supplementary appendix to that publication provided the actual or estimated number of patients receiving dialysis in 2010 for 202 countries. The number of dialysis patients in each ISN global region was the sum of the estimate for each country in that region and the total global dialysis population was the sum of each global region. The ratio of the trial site and population proportions results in an index, where 1.0 indicates that the number of trial sites is proportional to the number of dialysis patients in that region. An RI\>1.0 indicates relative over-representation and \<1.0, under-representation in large multicentre studies. The RI was reported for each of the 10 ISN regions.

Two exploratory analyses were performed to examine the relationship between RI and per capita gross domestic product (GDP). This was analysed using linear regression. GDP (in US\$) and population data for 2010 were obtained from the World Bank.[@R5] The change over time was analysed by comparing the number of RCTs recruiting from each region in the first half of the decade (2007--2011) to that in the second half of the decade (2012--2016) using exact logistic regression. Statistical analysis was conducted using Stata V.15.0.

Patient and public involvement {#s2-1}
------------------------------

Patients were not directly involved in the design or conduct of this research.

Results {#s3}
=======

From the 5229 records retrieved, 180 studies enrolling 76 127 participants from 6172 sites were identified for inclusion in the final analysis ([figure 1](#F1){ref-type="fig"}, [online supplementary table S1](#SP1){ref-type="supplementary-material"}). The majority of studies were conducted in a single country only (75.0%). Study characteristics are presented in [table 1](#T1){ref-type="table"}. The median number of participants was 208 (interquartile interval (IQI) 148--334) and the median number of sites was 15 (IQI 5--38). The USA accounted for 41.9% of sites with no other single country accounting for more than 10% of sites ([online supplementary table S2](#SP1){ref-type="supplementary-material"}). After North America with 44.5% of sites, Western Europe accounted for 26.9% of sites, followed by North-East Asia with 13.0% ([table 2](#T2){ref-type="table"}). Africa and South Asia had the lowest number of sites, accounting for only 0.2% and 0.3% of sites, respectively.
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###### 

Study characteristics

  Study characteristic                                          N (%) (n=180)
  ------------------------------------------------------------- ----------------
  Sponsor                                                       
   Commercial                                                   90 (50.0)
   Non-commercial                                               81 (45.0)
   Unknown                                                      9 (5.0)
  Type of study                                                 
   Parallel group                                               164 (91.1)
   Cluster                                                      11 (6.1)
   Crossover                                                    5 (2.8)
  Multicountry                                                  45 (25.0)
   Number of countries in multicountry studies---median (IQR)   7 (3--11)
  Included modality                                             
   Haemodialysis                                                147 (81.7)
   Both hemodialysis and peritoneal dialysis                    17 (9.4)
   Peritoneal dialysis                                          16 (8.9)
  Number of participants -- median (IQR)                        208 (148--334)
  Number of sites -- median (IQR)                               15 (5--38)
  Planned duration of follow-up (months) -- median (IQR)        7 (3--12)

###### 

Number of trial sites and patients by ISN region and representation index

  --------------------------------------------------------------------------------------------------------------------------------------------------------------
  Region                   Number of sites   Proportion of sites (%)   Dialysis patients\   Proportion of global dialysis patients (%)   Representation index†
                                                                       2010\*                                                            
  ------------------------ ----------------- ------------------------- -------------------- -------------------------------------------- -----------------------
  Eastern and Central\     424               6.9                       57 870               2.8                                          2.45
  Europe                                                                                                                                 

  Western Europe           1658              26.9                      249 671              12.2                                         2.20

  North America            2748              44.5                      443 139              21.6                                         2.06

  Russia and newly\        143               2.3                       33 830               1.7                                          1.36
  independent states                                                                                                                     

  South-East Asia and\     161               2.6                       86 529               4.2                                          0.62
  Oceania                                                                                                                                

  North-East Asia          802               13.0                      639 901              31.3                                         0.41

  Middle East              82                1.3                       103 124              5.0                                          0.27

  Latin America and the\   122               2.0                       274 205              13.4                                         0.15
  Caribbean                                                                                                                              

  South Asia               19                0.3                       78 111               3.8                                          0.08

  Africa                   13                0.2                       81 091               4.0                                          0.05

  Total                    6172              100.0                     2 047 471            100.0                                        
  --------------------------------------------------------------------------------------------------------------------------------------------------------------

\*Liyanage *et al* (2015).[@R1]

†Equals proportion of sites divided by the proportion of global dialysis patients. Note: Calculations were performed without the rounding displayed in the table.

ISN, International Society of Nephrology.

Data from Liyanage *et al* resulted in an estimate of 2 047 471 dialysis recipients in 2010. The largest share of these patients was from North-East Asia (31.3%, 639 901), followed by North America (21.6%, 443 139) and Western Europe (12.2%, 249 671) ([table 2](#T2){ref-type="table"}). Using these estimates and the site numbers to determine the RI, four regions were identified as well-represented (RI\>1) and six were under-represented (RI\<1) ([table 2](#T2){ref-type="table"}). As seen in [figure 2](#F2){ref-type="fig"}, the highest representation was in Eastern and Central Europe with an RI of 2.45, with 6.9% of the large multicentre study sites from an estimated 2.8% of the global dialysis population. Six regions were under-represented, with the lowest being 0.05 for Africa with only 0.2% of study sites from 4.0% of the global dialysis population ([table 2](#T2){ref-type="table"}). For every US\$10 000 in per capita GDP, the RI increased by 0.42 (95% CI 0.08 to 0.76, p=0.022) ([figure 3](#F3){ref-type="fig"}). This relationship explained half of the observed variation in RI (R-squared=0.50).
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![Representation index and per capita gross domestic product (GDP). NIS, newly independent states.](bmjgh-2019-001940f03){#F3}

The number of RCTs recruiting from each region in the first and second halves of the decade (2007--2016) is compared in [figure 4](#F4){ref-type="fig"}. Growth in the proportion of studies with sites in the region was greatest in the Middle East (OR 6.36 (95% CI 0.87 to 282.2), p=0.08), although the numbers in this region were small (1 vs. 10 studies) and the change did not reach significance. This was followed by North-East Asia (OR 2.23 (95% CI 1.06 to 4.89), p=0.03), which also recorded the largest numerical growth (14 vs. 42 studies). All other under-represented regions saw a relative decline in the proportion of studies including sites from that region.

![Change in number of RCTs from each ISN region between 2007--2011 and 2012--2016. ORs derived from exact logistic regression and indicate relative odds of an RCT including sites from each ISN region in 2012--2016 compared with 2007--2011. NIS, newly independent states; RCTs, randomised controlled trials.](bmjgh-2019-001940f04){#F4}

Discussion {#s4}
==========

This data clearly show extraordinary differences between global regions in terms of dialysis patient participation in large, multicentre RCTs---those RCTs most likely to provide a firm foundation for evidence-based practice. These differences are perhaps unsurprising as they parallel the long-standing disparities in income between global regions. However, they do highlight a number of areas of concern given that the number of dialysis patients is growing globally and in excess of economic growth. Growth in dialysis patients is particularly fast in Asia, with growth in demand for dialysis exceeding 10% per year in China, the Philippines and Malaysia, and over 30% per year in India.[@R6] Many regions with rapid growth in ESKD populations are also those found to be under-represented in large clinical trials.

The causes of the growth in the global dialysis population are complex, but include a commitment by a number of state governments to providing dialysis care within government-funded healthcare programmes. In resource-poor countries, it is particularly important that healthcare spending is effective and clinical research is conducted to inform clinicians and policymakers of the best use of their scarce resources. Much of the research conducted in high-income countries is restricted in its generalisability to countries with distinct populations and healthcare systems. Dialysis practices frequently differ, often driven by resource limitations. Examples include the frequent use of two times per week dialysis (in contrast to the almost ubiquitous three times per week schedules in developed countries) and dialyser reuse.[@R6] Cause of ESKD also differs, for example, some regions experience a high burden of chronic interstitial nephropathy (also known as chronic kidney disease of uncertain aetiology).[@R7] Furthermore, co-morbid illnesses differ, with a greater prevalence of some infectious diseases, such as hepatitis and tuberculosis, complicating the management of patients with ESKD.[@R6] Finally, many low-income and middle-income countries are facing a rising burden of non-communicable diseases in the presence of a continued need to invest scarce healthcare resources combatting persistently high rates of communicable diseases.[@R2] As a result, ESKD may be accorded relatively lower research priority. Yet, dialysis is a resource-intensive therapy and randomised research in the local context may help to ensure effective use of such scarce resources. These factors all underline the importance of locally relevant high-quality evidence.

Our data suggest that the number of large RCTs is growing, particularly in North-East Asia. This growth reflects rapid expansion in medical research funding (public and industry) in Asia, as compared with North America and Europe. However, reasons for change in RCT participation are undoubtedly complex, as evidenced by the significant reduction in the proportion of RCTs from Western Europe, representing a small real change (33 vs. 27 RCTs) and a large relative change. This is distinct from North America, where the decline was only relative, given a real increase in RCT participation (29 vs. 38 RCTs). At a broader level, annual growth in medical research investment was higher in Europe between 2004 and 2011 than in North America,[@R9] but the share of this originating from the public sector was lower[@R10]---which could result in different research priorities. Yet, most strikingly, the lack of growth in RCTs recruiting in South Asia, Latin America, the Caribbean and Africa indicates an ongoing need for investment in clinical trial infrastructure. India is a prime example, where the dialysis market is growing explosively,[@R11] while up to 90% of those with ESKD cannot afford KRT and of those who do start dialysis, more than half have to stop due to financial constraints.[@R7] Clearly, a larger evidence base supporting the efficacy and cost-effectiveness of local practices would be beneficial.

Conducting RCTs in many parts of the world is challenging due to resource scarcity, underdeveloped regulatory infrastructure and cultural differences. The importance of a clear legal and regulatory structure in encouraging larger studies is suggested by the position of Eastern and Central Europe, a region which is better represented than its GDP would predict. One explanation for this may be the legal harmonisation provided by the European Union which facilitates cross-border collaboration. To this may be added the lower cost of research staff and related activities in Eastern (as compared with Western) Europe. An effort among under-represented countries to ensure national clinical research regulations are clear and that application procedures are simplified (where possible) could be considered as a means for lower-resource countries to attract research investment. Collaboration between different global regions and sharing of expertise may provide advantages for researchers from both high-income and low-middle-income countries. The ISN has recognised this need and is building a network to foster RCTs.[@R12]

The global disparities identified appear comparable to other disciplines in internal medicine. For instance, Butler *et al* surveyed all cardiovascular trials in leading journals over a 10-year period and found that, of 1224 trials, 63.5% recruited only in North America or Western Europe, 7.7% outside this region and 28.8% multiregional, suggesting that some global regions may be similarly underserved by cardiovascular trials.[@R13] Additionally, that cardiovascular trials were two times the size of those identified in this study (median 452 participants) and recruited from more sites (median 20), suggests that the small size and relative paucity of trials in nephrology remains an ongoing problem, one not entirely explained by resources and infrastructure.[@R14] This is not to say that all trials should recruit patients from multiple global regions, or conversely, that trials should focus recruitment in a single region. Ideally, research networks can continue to develop in a way that permits broad international or regional collaboration as befits the clinical question and resources available for each RCT.

The primary limitation of our study is that we could not establish the country of origin of individual RCT participants. Site size is likely to vary between countries (eg, anecdotally, sites in China are substantially larger than those in Australia), meaning that, were study participation to be measured individually, the relative representation by region may differ. However, site participation is, in itself, a useful measure of the strength of randomised research in a region as each site represents a unit with the skills and resources to participate. Second, our estimates of site number may have been affected by the variability in study reporting of site location. Site numbers were sometimes established from lists of primary investigators in supplementary material, or from site listings on trial registries. We cannot always be sure whether this indicated the number of physical sites or networks of sites. Overall, the fact that establishing the number of sites in a particular country proved challenging at times, and that establishing the number of participants from each country was impossible, is clear evidence of the low priority afforded to generalisability by country or region by many authors and reviewers. Another limitation is that ISN Global Regions are not homogenous and large differences in study participation within regions have not been directly addressed. As we did not include clinical trial registries, regional databases or non-indexed literature in our search strategy, it is possible that some studies have been missed. Finally, our focus on large multicentre studies means that we cannot comment on the growth in smaller or single-centre studies on a global level. This means our results are not a summary of global clinical research activity in dialysis and should not be read as indicating a lack of high-quality researchers in some global regions.

Conclusions {#s5}
===========

This study demonstrated marked regional disparities in site participation in large multicentre RCTs enrolling dialysis patients. These differences may reflect more than simple wealth disparity. While there is evidence of growth in site participation in some regions, other regions, including some with rapidly growing populations of people on dialysis, remain under-represented. A coordinated effort to increase the numbers of large RCTs, including patients from all global regions, is required to ensure that patients and clinicians obtain access to high-quality and locally generalisable clinical evidence.
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